循环微小RNA作为骨质疏松与脆性骨折的生物标志物
研究在意大利7个医疗中心采集未使用抗骨吸收或骨形成药物的不同骨表型及脆性骨折患者血清,用下一代测序初筛50例骨质疏松患者与30例骨密度正常者,再用微滴数字PCR在213例中验证。测序发现5种微小RNA差异表达,验证显示骨质疏松患者循环miR-23a-3p和miR-21-5p水平可区分骨质疏松与骨密度正常者,miR-320a-3p升高与骨折相关且独立于骨密度。
要点
- 循环miR-23a-3p和miR-21-5p水平可区分骨质疏松患者与骨密度正常者。
- 循环miR-320a-3p升高与脆性骨折相关,且独立于骨密度。
- 作者认为循环miR-320a-3p可作为骨质疏松患者骨折风险的预后指标,需在前瞻性研究中确认。
核心结论
- 研究证实循环miR-23a-3p和miR-21-5p水平能够区分骨质疏松患者与骨密度正常者。
- 循环miR-320a-3p水平升高与骨折特异性相关且独立于骨密度,提示其可作为骨质疏松患者骨折风险的预后指标,需在前瞻性研究中确认。
研究设计与样本
- 样本采集自未接受任何抗骨吸收和/或骨形成药物治疗的不同骨表型和/或脆性骨折患者。
- 样本和数据采集自意大利7个医疗中心。
- 下一代测序预筛查纳入50例骨质疏松患者与30例骨密度正常者。
- 微滴数字聚合酶链反应验证纳入213例不同骨表型患者,包括经下一代测序分析队列。
主要发现
- 下一代测序鉴定出5种微小RNA(miR-8085、miR-320a-3p、miR-23a-3p、miR-4497、miR-145-5p)在无骨折骨质疏松病例与对照间差异表达。
- 微滴数字聚合酶链反应验证证实,骨质疏松患者(伴或不伴骨折)循环miR-23a-3p表达低于骨量减少者和正常者。
- 微滴数字聚合酶链反应显示,伴骨折骨质疏松患者循环miR-320a-3p表达升高,不伴骨折骨质疏松患者表达降低。
- 微滴数字聚合酶链反应分析显示,骨质疏松患者(伴或不伴骨折)miR-21-5p表达较骨量减少者和正常者显著升高,而下一代测序预筛查未发现此差异。
临床怎么用
- 作者认为循环miR-320a-3p可作为骨质疏松患者骨折风险的预后指标,需在前瞻性研究中确认。
局限性
- 作者指出循环miR-320a-3p作为骨折风险预后指标需在前瞻性研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Measurement of circulating microRNAs (miRNAs) as potential biomarkers of fragility fracture risk has recently become a subject of investigation. OBJECTIVE: Measure by next-generation sequencing (NGS), global miRNA expression in serum samples of osteoporotic subjects vs individuals with normal bone mineral density (BMD). DESIGN: Samples were collected from patients with different bone phenotypes and/or fragility fractures who did not receive any antiresorptive and/or bone-forming drug at the time of blood collection. SETTING: Samples and data were collected at 7 medical centers in Italy. PATIENTS: NGS prescreening: 50 osteoporotic patients vs 30 individuals with normal BMD. Droplet digital polymerase chain reaction (ddPCR) validation: 213 patients with different bone phenotypes, including the NGS-analyzed cohort. RESULTS: NGS identified 5 miRNAs (miR-8085, miR-320a-3p, miR-23a-3p, miR-4497, miR-145-5p) differentially expressed in osteoporosis cases without fractures vs controls. ddPCR validation confirmed lower c-miR-23a-3p expression in osteoporotic patients, with or without fracture, than in osteopenic and normal subjects and increased c-miR-320a-3p expression in osteoporotic patients with fracture and lower expression in osteoporotic patients without fracture. ddPCR analysis showed a significantly increased expression of miR-21-5p in osteoporotic patients, with or without fracture, than in osteopenic and normal subjects, not evidenced by the NGS prescreening. DISCUSSION: Our study confirmed levels of c-miR-23a-3p and c-miR-21-5p as able to distinguish osteoporotic patients and subjects with normal BMD. Increased levels of c-miR-320a-3p specifically associated with fractures, independently by BMD, suggesting c-miR-320a-3p as a prognostic indicator of fracture risk in osteoporotic patients, to be confirmed in prospective studies on incident fractures.
引用
- Ciuffi S, Marini F, Fossi C, et al. Circulating MicroRNAs as Biomarkers of Osteoporosis and Fragility Fractures. J Clin Endocrinol Metab. 2022. PMID: 35532548. doi:10.1210/clinem/dgac293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。